BCL2 and lymphoma: HDACi’s are currently being used to treat a variety of lymphomas and leukemias [5]–[7], and some of these studies, as well as the results we report here, indicate that the levels of pro- or anti-apoptotic BCL-2 family proteins may be important for determining sensitivity to HDACi treatment.